AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03339544
Drug: Celebrex premedication
RxNorm normalized name: Celebrex
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: celebrex (celecoxib) 200mg is a non-steroidal anti-infalmmatory drug with selective COX-2 inhibition.
Trial: NCT01542255
Drug: vinblastine
RxNorm normalized name: Vinblastine
DrugBank: Vinblastine (DB00570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg/m2 vinblastine given three times per week administered intravenously.
Trial: NCT02077803
Drug: Metformin XR, 500 mg
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).
Trial: NCT03796884
Drug: Linaclotide
RxNorm normalized name: Linaclotide
DrugBank: Linaclotide (DB08890)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT01542255
Drug: dacarbazine
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15 mg/m2 dacarbazine given three times per week for 3 weeks with 1 week rest
Trial: NCT01180764
Drug: Lovaza (Omega-3 acid ethyl esters)
RxNorm normalized name: omega-3 acid ethyl esters (USP) 1000 MG [Lovaza]
DrugBank: Omega-3-acid ethyl esters (DB09539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1g capsules, 4 capsules po daily
Trial: NCT04406389
Drug: Enoxaparin sodium
RxNorm normalized name: Enoxaparin Sodium
DrugBank: Enoxaparin (DB01225)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermediate Dose Prophylaxis Arm:~0.5 mg/kg subcutaneously every 12 hours if creatinine clearance greater than or equal to 30 ml/min --OR-- 0.5 mg/kg subcutaneously every 24 hours if creatinine clearance less than 30 ml/min~Therapeutic Dose Anticoagulation Arm:~1 mg/kg subcutaneously every 12 hours
Trial: NCT04406389
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermediate Dose Prophylaxis Arm:~7,500 units subcutaneously every 8 hours~Therapeutic Dose Anticoagulation Arm:~Dosed to target anti-Xa level 0.3 - 0.7 IU/mL or activated partial thromboplastin time (aPTT), according to institutional protocol
Trial: NCT04406389
Drug: Fondapariniux
RxNorm normalized name: Fondaparinux
DrugBank: Fondaparinux (DB00569)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermediate Dose Prophylaxis Arm:~2.5 mg daily subcutaneously~Therapeutic Dose Anticoagulation Arm:~Dose by weight:~* If greater than or equal to 100 kg: 10 mg daily~* If less than 100 kg but greater than or equal to 50 kg: 7.5 mg daily~* If less than 50 kg: 5 mg daily
Trial: NCT04406389
Drug: Argatroban
RxNorm normalized name: Argatroban
DrugBank: Argatroban (DB00278)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Therapeutic Dose Anticoagulation Arm:~Dosed according to institutional protocol
Trial: NCT03228498
Drug: Choline alphoscerate
RxNorm normalized name: Choline alphoscerate
DrugBank: Choline alfoscerate (DB04660)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choline alphoscerate 600 mg b.i.d plus Nimodipine 30 mg t.i.d
Trial: NCT00036062
Drug: Sivelestat
RxNorm normalized name: Sivelestat
DrugBank: Sivelestat (DB12863)
FDA approved: no
EMA approved: no
PMDA approved: yes
Trial: NCT00265967
Drug: Irbesartan
RxNorm normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Irbesartan 150-300 mg/d for 8 weeks
Trial: NCT00003735
Drug: topotecan hydrochloride
RxNorm normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: given by mouth
Trial: NCT00006063
Drug: pancrelipase with bicarbonate
RxNorm normalized name: Potassium Bicarbonate
DrugBank: Pancrelipase (DB00085)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00546234
Drug: tiotropium
RxNorm normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 mcg daily via Handihaler
Trial: NCT00106288
Drug: Micafungin
RxNorm normalized name: Micafungin
DrugBank: Micafungin (DB01141)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT00106288
Drug: Liposomal Amphotericin B
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT02715583
Drug: 11C-Acetate
RxNorm normalized name: 11C-ACETATE
DrugBank: Acetic acid C-11 (DB15111)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00744848
Drug: Bupivacaine HCl
RxNorm normalized name: bupivacaine HCl
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg Bupivacaine HCl
Trial: NCT01236859
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neurontin®, Pfizer
Trial: NCT00030095
Drug: 2-methoxyestradiol
RxNorm normalized name: 2-methoxyestradiol
DrugBank: 2-Methoxyestradiol (DB02342)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00334152
Drug: casopitant
RxNorm normalized name: casopitant
DrugBank: Casopitant (DB06634)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00703859
Drug: Dichloroacetate (DCA)
RxNorm normalized name: dichloroacetate
DrugBank: Dichloroacetic acid (DB08809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCA starting at an initial dose of 3mg/kg twice daily PO for consecutive days (days 1-5) on a 28 days cycle up to 6 cycles unless evidence of tumour progression. Each dose to be administered with food at the same time everyday 12 hours apart.
Trial: NCT03412500
Drug: Vancomycin equation-based method
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin dosage will be adjusted according to the equation-based method
Trial: NCT03412500
Drug: Vancomycin trough concentration method
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin dosage will be adjusted according to the trough concentration method
Trial: NCT02882737
Drug: Glucagon before exercise
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02882737
Drug: Glucagon after exercise
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02882737
Drug: Glucagon after resting
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03148756
Drug: Dalbavancin
RxNorm normalized name: Dalbavancin
DrugBank: Dalbavancin (DB06219)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1, and on Day 8.
Trial: NCT05567393
Drug: TAK-951
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-951 SC injection
Trial: NCT01690104
Drug: Rifampicin
RxNorm normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02633046
Drug: Acthar Gel
RxNorm normalized name: Acthar Gel
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acthar Gel 80 U/mL solution for subcutaneous injection
Trial: NCT01218399
Drug: Symbicort
RxNorm normalized name: Symbicort
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02322099
Drug: Alendronate
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: alendronate 70 mg tablets to be administered weekly for a total of 14 weeks, commencing 2 weeks prior to ART initiation
Trial: NCT02322099
Drug: Tenofovir disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Emtricitabine / tenofovir disoproxil fumarate 200 / 300 mg tablet administered once-daily with food (open-label) commencing 2 weeks after alendronate initiation and continuing for 48 weeks
Trial: NCT01601470
Drug: Sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil 50 mg single dose was administered alone for 1 days and in combination with LCZ696 400mg QD for 1 day
Trial: NCT04446871
Drug: 0.9% sodium chloride
RxNorm normalized name: LMD with 0.9% Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 500 cc of 0.9% sodium chloride solution for 6 h, once a day for a total of 3 doses.
Trial: NCT04446871
Drug: Methylene Blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 100 mg methylene blue in 500 cc of 0.9% sodium chloride solution for 6 h, once a day for a total of 3 doses.
Trial: NCT00003691
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04129086
Drug: Ketamine plus usual care
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bolus of .35 mg/kg Infusion start @ 0.15 mg/kg/hr; titrate range is 0.1 - 0.25 mg/kg/hr for 24 to 48 hours after admission and each subsequent major surgery plus multi-modal pain therapy considered as standard of care. Standard of care medications include Acetaminophen 1000 mg po q6 hours, Naproxen 500 mg po q12 hours, Gabapentin 300 mg po q8 hours and Lidocaine patch q 12 hours.
Trial: NCT02091921
Drug: Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients will be switched from clopidogrel to ticagrelor 90 mg twice daily for two weeks and the VerifyNow and VASP platelet reactivity assays repeated, samples will be collected before and 6±1 hours after the last ticagrelor dose.
Trial: NCT01160861
Drug: MEMP1972A
RxNorm normalized name: MEMP1972A
DrugBank: Quilizumab (DB15176)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeating ascending dose
Trial: NCT02223429
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 ml solution in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays
Trial: NCT02223429
Drug: Vasopressin
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 ml solution in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays
Trial: NCT00003691
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01331291
Drug: bosutinib
RxNorm normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Taken orally
Trial: NCT01918176
Drug: Palbociclib + Rabeprazole
RxNorm normalized name: Palbociclib
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Two Rabeprazole 20mg tablets will be given to subjects orally once daily for 7 days. Then on the same day at least 4 hours after the last dose of Rabeprazole, single dose of 125mg Palbociclib capsule will be given to subjects orally then followed by PK samplings at 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours.
Trial: NCT01630798
Drug: GI heptapeptide
RxNorm normalized name: GI heptapeptide
DrugBank: GI heptapeptide (DB15070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational Agent Name: GI heptapeptide, Linear, 7 amino acid peptide sequence ASYNYDA with a 5-FITC tag and NH2 terminus. Investigational Agent Administration (see SOP in Appendix C) ASYNYDA-GGGSK-(5-FITC)-NH2 0.8 mg lyophilized powder per single-use amber vial Lyophilized powder reconstituted with 5 ml of 0.9% NaCl Final 100 µM concentration for single, one-time topical application Entire 5 ml volume (100 uM concentration) will be sprayed topically onto esophagus by the nurse/physician during the procedure through a standard endoscopy spray catheter (Olympus Medical, Tokyo Japan, PW-5V-1)
Trial: NCT01343355
Drug: Tamibarotene
RxNorm normalized name: Tamibarotene
DrugBank: Tamibarotene (DB04942)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Oral administration of tamibarotene 2 mg daily over a period of 12 weeks, then 4mg daily for another 12 weeks.
Trial: NCT00425126
Drug: Epoetin Alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01293006
Drug: suvorexant
RxNorm normalized name: Suvorexant
DrugBank: Suvorexant (DB09034)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: one tablet (30 or 40 mg suvorexant depending on participant age: 40 mg for participants \<65 years of age and 30 mg for participants ≥65 years of age), orally, once daily, for 4 consecutive days
Trial: NCT03081598
Drug: PBI-4050
RxNorm normalized name: PBI-1402
DrugBank: PBI-1402 (DB05480)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft gelatine capsule containing 200 mg of the active ingredient per capsule
Trial: NCT03027219
Drug: Alprostadil
RxNorm normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vasodilator for anastomosis-site of free flap
Trial: NCT00278941
Drug: Quetiapine Fumarate Sustained Release
RxNorm normalized name: Quetiapine Fumarate
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00357149
Drug: Docetaxel, cisplatin and 5-FU treatment followed by concomitant cisplatin, 5-FU and radiotherapy
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00357149
Drug: Concomitant cisplatin, 5-FU and radiotherapy
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02759562
Drug: Andecaliximab
RxNorm normalized name: Andecaliximab
DrugBank: Andecaliximab (DB17564)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via subcutaneous injection
Trial: NCT01726816
Drug: Probucol 250mg/day
DrugBank: Probucol (DB01599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Probucol 250mg + Placebo
Trial: NCT01726816
Drug: Probucol 500mg/day
DrugBank: Probucol (DB01599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Probucol 500mg + Placebo
Trial: NCT00438464
Drug: Finasteride
RxNorm normalized name: Finasteride
DrugBank: Finasteride (DB01216)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03690947
Drug: Intravitreal Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All subjections received 3 initial Ranibizumab injections
Trial: NCT03690947
Drug: Intravitreal Ranibizumab as needed
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: After 3 initial Ranibizumab injections, Ranibizumab will be injected as needed till BCVA reaches stabilization
Trial: NCT03472040
Drug: BCX7353
RxNorm normalized name: BCX7353
DrugBank: Berotralstat (DB15982)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: BCX7353 mg oral capsules administered once daily
Trial: NCT03911869
Drug: encorafenib
RxNorm normalized name: encorafenib
DrugBank: Encorafenib (DB11718)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: taken orally
Trial: NCT03911869
Drug: binimetinib
RxNorm normalized name: binimetinib
DrugBank: Binimetinib (DB11967)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: taken orally
Trial: NCT03029676
Drug: benzodiazepines
RxNorm normalized name: 1,3-dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one
DrugBank: Nitrazepam (DB01595)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sedative
Trial: NCT00432913
Drug: Eicosapentaenoic Acid (EPA)
RxNorm normalized name: Eicosapentaenoic Acid (EPA)
DrugBank: Icosapent (DB00159)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Either 2 x 500mg EPA capsules in the morning and evening (2g per day EPA) or 1 x 500mg EPA and 1 x placebo in the morning and evening (1g per day EPA)
Trial: NCT02925559
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The active treatment will include a 10 mg dose of dapagliflozin orally once a day.
Trial: NCT02925559
Drug: Gliclazide MR
RxNorm normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As comparator, gliclazide MR will be administered at a dose of 120 mg orally once a day.
Trial: NCT00154193
Drug: cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will receive maintenance triple immunosuppression according to local practice consisting of Sandimmun Neoral, MMF/ECMPA or azathioprin and steroids.
Trial: NCT01939093
Drug: Diazepam
RxNorm normalized name: Diazepam
DrugBank: Diazepam (DB00829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: If subjects had aggressive or violent symptoms and immediate symptom control was needed, 10 mg of diazepam (intravenous injection) every 4 hours is allowed for symptom control.
Trial: NCT00630708
Drug: Benazepril
RxNorm normalized name: Benazepril
DrugBank: Benazepril (DB00542)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg per day
Trial: NCT00630708
Drug: Losartan
RxNorm normalized name: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg per day
Trial: NCT00630708
Drug: Benazepril+Losartan
DrugBank: Benazepril (DB00542)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: combination treatment of 10 mg benazepril and 50 mg losartan per day
Trial: NCT00703170
Drug: Temsirolimus
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04503850
Drug: Mirabegron 50 MG
RxNorm normalized name: mirabegron 50 MG
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirabegron 50 mg daily dose and follow Up of erectile function using international index of erectile function 5 scoring system
Trial: NCT00365768
Drug: Glutamine
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally twice daily for 21 days
Trial: NCT01089569
Drug: Exenatide
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mcg BID (twice daily) for 1 month increasing to 10 mcg BID for the remainder of the study
Trial: NCT01089569
Drug: Insulin Glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: .1 unit per kg to start, titrated based on Continuous Glucose Monitoring results
Trial: NCT01407848
Drug: Furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients received nebulised Furosemide iv solution 1 mg/kg (4x/d) for max.3 consecutive days.
Trial: NCT03902041
Drug: Eltrombopag
RxNorm normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The patients will receive Eltrombopag treatment after transplantation
Trial: NCT04516655
Drug: chidamide combined with rituximab and high-dose methotrexate
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: chidamide 20 mg biw PO day1-14 and rituximab 375 mg/m2 IV given on day 1 and methotrexate 3.5g/m2 IV given on day 2 of every 21-day cycle for 6 cycles in untreated patients with primary central nervous system lymphoma
Trial: NCT03030768
Drug: PrEP
RxNorm normalized name: X-Prep
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An integrated, phased safer conception intervention that focuses on ART use by the HIV-1 infected partner, PrEP use by the HIV-1 uninfected partner, and timed condomless sex during the peri-conception period.
Trial: NCT02628951
Drug: Ramucirumab
RxNorm normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ramucirumab injection for intravenous (I.V.) use, supplied in single-use 500-mg/50-mL vials containing 10 mg/mL of product in histidine buffer, administered as an I.V. infusion after dilution at 8 mg/kg every 2 weeks in the absence of disease progression, toxicity requiring cessation, or withdrawal for any other reason.
Trial: NCT02628951
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel will be administered at a dose of 80 mg/m2 on Days 1, 8 and 15 of a 28-day cycle in the absence of disease progression, toxicity requiring cessation, or withdrawal for any other reason.
Trial: NCT04624217
Drug: SHR-1701
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDL1/TGFβ
Trial: NCT00990249
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Test Dose 32 mg/m\^2 by vein over 45 minutes on Day -8; following doses on Days -6 to -3 derived from pharmacokinetic (PK) testing done up to 11 times over 11 hours after test dose.
Trial: NCT00990249
Drug: Clofarabine
RxNorm normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 40 mg/m\^2 by vein over 1 hour daily Day -6 through Day -3
Trial: NCT00990249
Drug: Thymoglobulin
RxNorm normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg on Day -3, 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1; only patients with HLA nonidentical or unrelated donors
Trial: NCT00844324
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Formulation:Oral suspensionStrength:1 mg/mLDose: 32 mg, single dose
Trial: NCT00844324
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Formulation:Oral suspensionStrength:1.6 mg/mLDose: 32 mg, single dose
Trial: NCT00545467
Drug: Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole will be given as a fixed does, 15 mg/day, orally throughout 8 weeks in the 2 arms.